HC-N2, an active ingredient from ethanol extracts of a Chinese herbal medicine Hedychium coronarium Koenig (Zingiberaceae), has demonstrated excellent efficacy and safety profiles in diabetic animal models. Four weeks treatment with HC-N2 at 60 mg/kg significantly reduced fasting blood glucose and OGTT incremental glucose AUC by 43% (p<0.01) and 62% (p<0.001); respectively. In addition, preclinical repeat-dose toxicity study in rat and in dog both revealed NOAEL to be 972 mg/kg/day which provided a safety margin of 10 folds over the maximal recommended starting dose in phase 1 clinical study.

VN-B101, a 500 mg tablet contains 165mg active ingredient HC-N2 with 335 mg of inactive excipients, would be used in the clinical trials. The clinical study protocol of VN-B101 tablet received the IND approval from USFDA and TFDA in 2012 and 2016; respectively.

One of the major objectives of this study was to evaluate effects of VN-B101 as an adjuvant to metformin (MET) in patients with uncontrolled type 2 diabetes mellitus (T2DM). This trial was a single center, open-label, phase-I study (NCT03033433) consisting of two stages: Stage 1 was a dose-escalation study to assess the safety and tolerability profile of three escalating doses of VN-B101 (1, 2, and 4 tablets; qd; for 7 days) in healthy subjects, while Stage 2 applied VN-B101 as add-on treatment to MET in T2DM. There was no AEs or SAE found in stage 1 and stage 2 subjects. In addition, the combination treatment significantly reduced OGTT incremental glucose AUC by additional 35% (p<0.05) compared to MET monotherapy.

In summary, VN-B101 as add-on therapy to MET is safe and efficacious in T2DM inadequately controlled by MET alone. The inspiring study results encourage further clinical studies to be conducted.


H. Chen: None. P. Wang: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.